Skip to main content
. Author manuscript; available in PMC: 2011 Sep 30.
Published in final edited form as: Acta Neuropathol. 2010 Mar 31;119(5):523–541. doi: 10.1007/s00401-010-0679-9

Fig. 1.

Fig. 1

Schematic diagram of APP and APP metabolites, including APP βCTF and Aβ, cleavage sites in APP of α, β and γ-secretases, and domains recognized by representative antibodies. Aβ/APP antibodies, such as 6E10 and 4G8, recognize full-length APP, CTFs and Aβ. Antibodies P2-1 and 369 are directed against the N- and C-terminal regions of full-length APP, respectively. Antibody 3D6 is specific to the free N-terminus of Aβ1-x and βCTF; this antibody will not recognize full-length APP or other APP CTFs. Antibodies MBC40 and MBC42 specifically recognize the free C-terminus of Aβ40 and Aβ42, respectively, and do not react against full-length APP or APP CTFs.